LUCAS study shows equivalence between anti-VEGF drugs following inject-and-extend regimen

LONDON – A prospective study comparing the safety and efficacy of anti-VEGF treatment for age-related macular degeneration with ranibizumab and bevacizumab in nine clinical centers in Norway showed equivalent effects on vision, a need for more injections with bevacizumab, and a small and comparable number of serious adverse events.The LUCAS study enrolled 441 patients randomly assigned to receive ranibizumab (Lucentis, Genentech) or bevacizumab (Avastin, Genentech) in an inject-and-extend regimen. One injection was performed at every visit, initially every 4 weeks, until no signs of active neovascularization was seen. The next (Read more...)

Full Story →